Want to see ACIU full AI Analyst Report?
Top Page
AC Immune SA
(NASDAQ:ACIU)
Select Model
Select Model
Rating:47Neutral
Price Target:
$3.00
▲(34.53% Upside)
Action:Reiterated
Date:07/01/26
The score is primarily constrained by weak financial performance—persistent losses and a 2025 return to heavy cash burn—despite the benefit of low leverage on the balance sheet. Technicals add further pressure as the stock trades below key longer-term moving averages. Valuation contributes only a modest offset because the negative P/E reduces the usefulness of earnings-based valuation and there is no dividend yield provided.
Positive Factors
Pipeline validation and regulatory progress
Fast Track status and encouraging early immunogenicity data support continued advancement of ACI-7104. U.S. trial expansion may improve development efficiency and strengthen AC Immune’s proprietary Parkinson’s franchise over the next several years.
Negative Factors
Persistent unprofitability and cash burn
AC Immune remains dependent on external funding because clinical R&D costs exceed internally generated revenue. Continued losses and renewed cash burn could consume reserves faster than planned and increase reliance on partnerships, grants or equity issuance.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline validation and regulatory progress
Fast Track status and encouraging early immunogenicity data support continued advancement of ACI-7104. U.S. trial expansion may improve development efficiency and strengthen AC Immune’s proprietary Parkinson’s franchise over the next several years.
Read all positive factors
AC Immune SA (ACIU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$291.07M
Dividend YieldN/A
Average Volume (3M)241.73K
Price to Earnings (P/E)―
Beta (1Y)1.32
Revenue Growth-33.68%
EPS Growth4.48%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding101,773,575
10 Day Avg. Volume208,511
30 Day Avg. Volume241,726
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)5.58
Price to Sales (P/S)70.23
P/FCF Ratio-3.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.00Price Target Upside348.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$20.14M
AC Immune SA Business Overview & Revenue Model
Company Description
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding...
How the Company Makes Money
AC Immune primarily makes money through research collaborations and licensing arrangements with larger pharmaceutical partners rather than through product sales (as a clinical-stage company). Its revenue model typically includes: (1) upfront payme...
AC Immune SA Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.51M | 3.57M | 27.31M | 14.80M | 3.94M | 0.00 |
| Gross Profit | 17.51M | 3.57M | -35.26M | -39.80M | 3.94M | 0.00 |
| EBITDA | -41.99M | -67.75M | -48.62M | -51.83M | -68.03M | -70.01M |
| Net Income | -43.16M | -70.45M | -50.92M | -54.23M | -70.75M | -73.00M |
Balance Sheet | ||||||
| Total Assets | 150.40M | 154.43M | 230.91M | 182.81M | 185.94M | 261.44M |
| Cash, Cash Equivalents and Short-Term Investments | 75.36M | 91.41M | 165.49M | 103.05M | 122.59M | 198.22M |
| Total Debt | 4.10M | 4.55M | 5.43M | 3.50M | 2.80M | 2.91M |
| Total Liabilities | 115.23M | 109.49M | 118.64M | 22.17M | 16.95M | 29.46M |
| Stockholders Equity | 35.17M | 44.93M | 112.27M | 160.64M | 168.99M | 231.98M |
Cash Flow | ||||||
| Free Cash Flow | -34.95M | -67.01M | 65.27M | -61.21M | -74.81M | -68.32M |
| Operating Cash Flow | -34.79M | -66.15M | 65.84M | -60.41M | -73.57M | -65.69M |
| Investing Cash Flow | 36.57M | 60.69M | -105.29M | 65.64M | 23.76M | -53.66M |
| Financing Cash Flow | -513.95K | -974.14K | -1.12M | 43.25M | -1.35M | 40.75M |
AC Immune SA Technical Analysis
Positive
2.23
Price Trends
2.43
Positive
2.63
Positive
2.86
Positive
Market Momentum
0.12
Negative
69.92
Neutral
84.62
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACIU, the sentiment is Positive. The current price of 2.23 is below the 20-day moving average (MA) of 2.49, below the 50-day MA of 2.43, and below the 200-day MA of 2.86, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 69.92 is Neutral, neither overbought nor oversold. The STOCH value of 84.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ACIU.
AC Immune SA Risk Analysis
AC Immune SA disclosed 82 risk factors in its most recent earnings report. AC Immune SA reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AC Immune SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $460.74M | -4.01 | -196.63% | ― | 20.83% | 73.89% | |
54 Neutral | $1.31B | -4.04 | -82.68% | ― | ― | -37.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.34B | -0.07 | -91.63% | ― | ― | 69.48% | |
47 Neutral | $291.07M | -5.32 | -99.17% | ― | -33.68% | 4.48% | |
46 Neutral | $256.81M | -2.09 | -531.04% | ― | -82.91% | 6.27% | |
44 Neutral | $407.98M | -6.94 | 72.64% | ― | 51.98% | 17.68% |
* Healthcare Sector Average
ACIU
AC Immune SA
2.92
0.82
39.05%
EDIT
Editas Medicine
3.28
0.55
20.15%
ALEC
Alector
2.36
0.00
0.00%
MLTX
MoonLake Immunotherapeutics
15.56
-38.94
-71.45%
FHTX
Foghorn Therapeutics
6.85
1.32
23.87%
VOR
Vor Biopharma
24.01
-17.59
-42.28%
AC Immune SA Corporate Events
AC Immune posts positive first‑in‑human data for NLRP3 inhibitor ACI‑19764
Aug 20, 2026
On August 20, 2026, AC Immune reported positive preliminary data from a first‑in‑human Phase 1/1b trial of ACI‑19764, its orally available, brain‑penetrant small‑molecule inhibitor of the NLRP3 inflammasome. In health...
AC Immune Wins FDA Fast Track for ACI-7104 in Early Parkinson’s Disease
Aug 11, 2026
On August 11, 2026, AC Immune announced that the U.S. FDA granted Fast Track designation and cleared an IND for its wholly owned anti-alpha-synuclein active immunotherapy, ACI-7104, in early-stage Parkinson’s disease, enabling expansion of i...
AC Immune Files First-Half 2026 Results and Corporate Update on Form 6-K
Aug 5, 2026
On August 5, 2026, AC Immune SA filed a Form 6-K in the United States, furnishing unaudited interim condensed consolidated financial statements for the six months ended June 30, 2026, along with management’s discussion and updated Articles o...
AC Immune Unveils 12-Month Interim Data from ACI-24 Alzheimer’s Trial and Expands Takeda-Backed Program
Jun 30, 2026
On June 30, 2026, AC Immune SA reported 12‑month interim results from the first three cohorts of its Phase 1b/2 ABATE trial evaluating ACI‑24, an anti‑amyloid beta active immunotherapy, in 74 patients with prodromal AlzheimerR...
AC Immune Shareholders Back Capital Band, Governance Slate and Pay Caps at June 11 AGM
Jun 11, 2026
On June 11, 2026, AC Immune SA held its Annual General Meeting, where shareholders approved the company’s 2025 IFRS consolidated and statutory financial statements and endorsed the 2025 compensation report, despite the year’s CHF 67.6 ...
AC Immune Secures $4 Million Goradia Foundation Grant to Extend Phase 2 Parkinson’s Trial
Jun 11, 2026
On June 11, 2026, AC Immune SA said it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation to extend Part 1 of its ongoing Phase 2 VacSYn trial of ACI-7104, an anti-alpha-synuclein active immunotherapy, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.